Injective (INJ): EVM Testnet Launch, Strategic Partnerships, and Bullish Momentum in 2025

1. Executive Summary

Injective (INJ) has been making waves in the decentralized finance (DeFi) ecosystem, with significant developments fueling bullish sentiment. Over the past week, Injective unveiled its EVM-compatible testnet, formed a strategic council with Google Cloud and Deutsche Telekom, and filed for an INJ Staked ETF to attract institutional investors. These moves have not only boosted network activity but also driven INJ’s price above critical resistance levels. With a current price of $13.44 and a 10.71% daily gain, Injective is positioned for further growth as it solidifies its role in DeFi and asset tokenization.

2. Recent Market Developments

EVM Testnet Launch Fuels Growth
Injective’s EVM-compatible testnet launched on July 9, enhancing compatibility with Ethereum-based assets. This milestone has driven a 1,700% increase in daily active addresses since January, reaching over 82,000. The testnet positions Injective as a frontrunner in real-world asset (RWA) tokenization, attracting developers and users alike.

Strategic Partnerships with Industry Giants
Injective formed the Injective Council on July 12, partnering with Google Cloud and Deutsche Telekom. These alliances will accelerate institutional adoption and innovation in DeFi. The partnerships have also bolstered investor confidence, contributing to a 15% price surge.

INJ Staked ETF Filing
On July 14, Injective filed for an INJ Staked ETF, aiming to bring staking rewards to institutional investors in a regulated framework. This move bridges traditional finance and DeFi, opening the door for increased institutional capital inflow.

Regulatory Collaboration
Injective is collaborating with the SEC to shape crypto regulations in the U.S., signaling its commitment to compliance and sustainable growth. While the long-term impact remains neutral, this initiative enhances Injective’s reputation as a regulatory-friendly platform.

Market Momentum and Price Action
Injective broke above the $12.50 resistance on July 14, targeting $12.88 and beyond. The bullish trend continued, with INJ currently trading at $13.44, supported by strategic developments and growing market interest.

3. Technical Analysis

Current Price: $13.44
24h Change: +10.71%

Moving Averages:
– Short-term momentum is strong, with SMA7 at $12.63 and EMA12 at $12.17, both supporting a bullish trend.
– Long-term indicators such as SMA_200 at $13.15 suggest that INJ has reclaimed its upward trajectory.

Momentum Indicators:
– RSI(14): 65.84, indicating bullish conditions nearing overbought territory.
– MACD: Positive at 0.4181, with a strong histogram of 0.3116, signaling continued upward momentum.
– Stochastic Oscillator (%K: 98.16): Indicates overbought conditions, suggesting potential consolidation or pullback in the short term.

Key Levels:
– Resistance 1: $13.50 (current test level)
– Resistance 2: $15.48 (next major target)
– Support 1: $10.07
– Support 2: $8.95

Bollinger Bands: INJ is trading above the upper band ($13.40), confirming strong upward momentum, though a minor pullback is likely to stabilize the price.

4. Trading Strategy and Signals

Short-Term Strategy:
Traders can consider entering positions on pullbacks toward the $12.96 pivot or the $13.15 SMA_200 level, targeting $15.48 in the near term. Given the overbought conditions, tight stop-losses near $12.50 are advised to mitigate downside risk.

Medium to Long-Term Strategy:
With Injective’s focus on institutional adoption and asset tokenization, holding INJ for the long term could yield substantial gains. Accumulation near support levels of $10.07 or $8.95 during market corrections might be a prudent strategy.

5. Price Predictions and Outlook

Injective’s recent developments point to a bullish trajectory:
– Short-Term Price Predictions: INJ is likely to test $15.48 if it sustains momentum above $13.50.
– Long-Term Projections: With institutional adoption and regulatory clarity, INJ could reclaim its 52-week high of $34.02 in the coming quarters, provided broader market conditions remain favorable.

6. Risk Analysis

While the sentiment around Injective is overwhelmingly positive, risks remain:
1. Regulatory Uncertainty: Collaboration with the SEC is promising, but any unfavorable rulings could impact Injective’s growth.
2. Overbought Conditions: Technical indicators such as RSI and Stochastic Oscillator suggest short-term overheating, which could lead to pullbacks.
3. Market Volatility: Broader crypto market trends could overshadow Injective’s progress, particularly in the event of bearish macroeconomic conditions.
4. Delisting Impact: The recent delisting of INJ by Cointree may dampen sentiment in certain markets, though the long-term impact is negligible.

7. Conclusion

Injective (INJ) is poised for continued growth, driven by strategic developments such as the EVM testnet launch, institutional partnerships, and the INJ Staked ETF filing. Technical indicators support a bullish outlook, with the potential to test $15.48 in the short term. However, traders should remain cautious of overbought conditions and potential regulatory headwinds. For long-term investors, Injective’s focus on DeFi innovation and asset tokenization makes it a promising project in the evolving crypto landscape.

Image source: Shutterstock